Last reviewed · How we verify
MenACYW-135 conjugate vaccine
MenACYW-135 is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, Y, and W-135.
MenACYW-135 is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, Y, and W-135. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.
At a glance
| Generic name | MenACYW-135 conjugate vaccine |
|---|---|
| Also known as | MENVEO® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains polysaccharide capsules from four meningococcal serogroups conjugated to a protein carrier, which enhances immunogenicity and promotes T-cell dependent immune responses. This conjugation approach improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive meningococcal disease caused by these four serogroups.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China (PHASE3)
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MenACYW-135 conjugate vaccine CI brief — competitive landscape report
- MenACYW-135 conjugate vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI